Sichuan Kelun Pharmaceutical Co., Ltd.
Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products. In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology. Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.
Sichuan Kelun Pharmaceutical Co., Ltd.
Founded in 1996, Kelun has now formed a "Pin"-shaped architecture operation platform composed of Kelun Pharmaceutical, Chuanning Biotechnology and Kelun Botai, with a total market value of over 100 billion yuan. In 2018, Kelun was named "Manufacturing Single Champion Demonstration Enterprise" for his global advantages in large-capacity injections. Sichuan Kelun Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange in June 2010, and immediately launched the 10 billion industry investment plan and began to implement the development strategy of "three-in-one developments, innovative growth". The first engine maintains Kelun's leading position in the infusion field through continuous industrial upgrading and variety structure adjustment; the second engine builds from intermediates, raw materials to preparations through innovative development and utilization of high-quality natural resources. The third engine accumulates the ultimate driving force for the everlasting enterprise foundation through the construction of the R&D system and diversified technological innovation. In the field of infusion, Kelun has achieved comprehensive industrial upgrading, and has the profitability of both high-end manufacturing and new materials, occupying a strategic high ground for technological innovation and quality benchmarks. Columbia has established a closed responsibility system from drug research and development, production and manufacturing, logistics and transportation to terminal use to ensure product quality and safety. The leading products have been exported in batches and enjoy a high reputation in more than 50 countries and regions. The stand-up bag® independently developed by Kelun is the first at home and abroad. It has more than 20 patents and has won the National Science and Technology Progress Award. It has higher safety and cost-effectiveness than traditional infusions, and has great application value in reducing energy consumption and environmental protection, representing the direction of development of Chinese infusion products. In the field of antibiotics, the company has established Yili Chuanning Biotechnology Co., Ltd. to produce erythromycin thiocyanate and cephalosporin series intermediates. Through R&D testing, upgrading and optimization, innovative cooperation, and the introduction of advanced domestic and foreign technology equipment, Sichuan Ning has been approved to build a National Environmental Protection Antibiotic Bacterial Slag Harmless Treatment and Resource Utilization Engineering Technology Center, solving the source problems of the antibiotic industry. In December 2022, Chuanning Biotech was successfully listed on the Shenzhen Stock Exchange GEM and entered the field of synthetic biology. Kelun has applied for more than 1,300 invention patents and obtained more than 700 invention patents. He has launched the development of more than 500 major drugs in many diseases such as tumors, bacterial infections, parenteral nutrition, etc.; since 2017, it has been approved for marketing every year. More than 20 items have become the leading generic drug enterprise in China, and has become the leading supplier of national centralized drug procurement with a winning rate of nearly 90%. At the same time, more than ten innovations are used to treat major diseases such as tumors, autoimmunity, inflammation, and metabolism. The drug project is in its clinical stage, with multiple clinical trials being a global multi-center research. Multiple projects work together with European and American partners to deploy global clinical research and are carried out simultaneously in multiple countries including China and Europe and the United States to achieve the synergy of pipelines and technology platforms. Effects, maximize the global value of pipelines.
Merro Pharmaceutical Co., Ltd.
In 1925, Meiluo Pharmaceutical was founded at Dalian Mandroit Institute of Health; in 1957, it successfully developed erythromycin in China; in 1989, it jointly established Pfizer Pharmaceutical Co., Ltd.; in 2000, it passed the country GMP certification. In the past century, Mero has never stopped developing. In 2005, it obtained TGA international certification, and in the same year metformin hydrochloride tablets were exported to New Zealand; in 2014, the solid preparation workshop passed the US FDA certification; in 2015, it acquired the Polygen Pharmaceutical Factory in the United States; in 2017, sustained release preparation products were exported to Australia, with multiple ANDA products were approved in the United States. Based on the existing 200 products, Meilu focuses on developing slow-release preparations and biological agents, promote extensive cooperation in products and technologies in the international pharmaceutical market, and continuously improve the company's innovation capabilities to build a factory in line with advanced countries such as Europe and the United States. The center vigorously explores the international and domestic markets and builds it into an international pharmaceutical company that uses technology, provides excellent services and is proficient in changes. Through the complete sales network service of 30 provinces and cities, Meiluo's products have entered more than 10,000 medical institutions of various types in China to achieve terminal sales in more than 50,000 pharmacies. It has achieved strategic partnerships with the top KA customers in the country and has been in 8 The large pharmaceutical e-commerce platform has carried out in-depth cooperation through three major channels to achieve coverage of prescription drugs, OTC products, health products, cleaning products and disinfection products, providing health solutions to consumers of all ages across the country. In the future, Meiluo Pharmaceutical will continue to promote pharmaceutical innovation, drive the upgrading of pharmaceutical manufacturing business and marketing, and create a healthier and better future for mankind. Meiluo exists only for health.
Merro Pharmaceutical Co., Ltd.
In 1925, Meiluo Pharmaceutical was founded at Dalian Mandroit Institute of Health; in 1957, it successfully developed erythromycin in China; in 1989, it jointly established Pfizer Pharmaceutical Co., Ltd.; in 2000, it passed the country GMP certification. In the past century, Mero has never stopped developing. In 2005, it obtained TGA international certification, and in the same year metformin hydrochloride tablets were exported to New Zealand; in 2014, the solid preparation workshop passed the US FDA certification; in 2015, it acquired the Polygen Pharmaceutical Factory in the United States; in 2017, sustained release preparation products were exported to Australia, with multiple ANDA products were approved in the United States. Based on the existing 200 products, Meilu focuses on developing slow-release preparations and biological agents, promote extensive cooperation in products and technologies in the international pharmaceutical market, and continuously improve the company's innovation capabilities to build a factory in line with advanced countries such as Europe and the United States. The center vigorously explores the international and domestic markets and builds it into an international pharmaceutical company that uses technology, provides excellent services and is proficient in changes. Through the complete sales network service of 30 provinces and cities, Meiluo's products have entered more than 10,000 medical institutions of various types in China to achieve terminal sales in more than 50,000 pharmacies. It has achieved strategic partnerships with the top KA customers in the country and has been in 8 The large pharmaceutical e-commerce platform has carried out in-depth cooperation through three major channels to achieve coverage of prescription drugs, OTC products, health products, cleaning products and disinfection products, providing health solutions to consumers of all ages across the country. In the future, Meiluo Pharmaceutical will continue to promote pharmaceutical innovation, drive the upgrading of pharmaceutical manufacturing business and marketing, and create a healthier and better future for mankind. Meiluo exists only for health.
Beijing Hanmi Pharmaceutical Co., Ltd.
Lidong is a lactulose oral solution product launched by Beijing Hanmei in 2006. Beijing Hanmei Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Hanmei) was established in March 1996 and is located in the beautiful environment of Beijing Shunyi Airport Development Zone, covering an area of 13,600 square meters. In addition to its headquarters, Beijing Hanmei also has a research center, a GMP factory and a sales team all over the country. In 2008, it established a "Business Center" with international advanced level, integrating "research and development, production and sales". Three are in one. Among them, the GMP factory was carefully designed and built strictly in accordance with the GMP standards. It passed the GMP certification of the State Administration of Drug Administration in December 2001 and officially put into production and use, and passed the new version of the GMP certification at the end of 2015. The research center has an area of nearly 4,000 square meters, including biological laboratories, chemical synthesis laboratories and pharmacological toxicology laboratories. It is equipped with a variety of world-class drug research equipment, and is equipped with advanced foreign research and development centers, Korean and American pharmaceutical headquarters, Korean and American fines Chemical plants and formula R&D centers work closely together to form an advanced and high-end global R&D network. The sales team covers all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties in China. The company's product business involves pediatric products, gastroenterology products, orthopedic products, anti-infective drugs and other fields. 98% of the products are produced in China. The main products include Mommy Ai, Yi Tanjing, Mei Changan, Li Dong, and Aceclofenac. More than a dozen varieties, including Ruimai, etc. Among them, Mommy Ai and Yi Tanjing have become basic regular medicines for children in China and are very popular among doctors and children's parents. For the precious life of mankind, Beijing, South Korea and the United States want to produce better medicines. In order to realize the common ideal, Beijing, South Korea and the United States will strive for it. For social progress and personal progress, Beijing, South Korea and the United States will do their best to do their best. In the future, Beijing, South Korea and the United States will be committed to producing more high-quality and high-tech drugs and contribute to the country's medical industry.
Beijing Hanmi Pharmaceutical Co., Ltd.
Lidong is a lactulose oral solution product launched by Beijing Hanmei in 2006. Beijing Hanmei Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Hanmei) was established in March 1996 and is located in the beautiful environment of Beijing Shunyi Airport Development Zone, covering an area of 13,600 square meters. In addition to its headquarters, Beijing Hanmei also has a research center, a GMP factory and a sales team all over the country. In 2008, it established a "Business Center" with international advanced level, integrating "research and development, production and sales". Three are in one. Among them, the GMP factory was carefully designed and built strictly in accordance with the GMP standards. It passed the GMP certification of the State Administration of Drug Administration in December 2001 and officially put into production and use, and passed the new version of the GMP certification at the end of 2015. The research center has an area of nearly 4,000 square meters, including biological laboratories, chemical synthesis laboratories and pharmacological toxicology laboratories. It is equipped with a variety of world-class drug research equipment, and is equipped with advanced foreign research and development centers, Korean and American pharmaceutical headquarters, Korean and American fines Chemical plants and formula R&D centers work closely together to form an advanced and high-end global R&D network. The sales team covers all provinces, autonomous regions, municipalities directly under the central government and hundreds of cities and counties in China. The company's product business involves pediatric products, gastroenterology products, orthopedic products, anti-infective drugs and other fields. 98% of the products are produced in China. The main products include Mommy Ai, Yi Tanjing, Mei Changan, Li Dong, and Aceclofenac. More than a dozen varieties, including Ruimai, etc. Among them, Mommy Ai and Yi Tanjing have become basic regular medicines for children in China and are very popular among doctors and children's parents. For the precious life of mankind, Beijing, South Korea and the United States want to produce better medicines. In order to realize the common ideal, Beijing, South Korea and the United States will strive for it. For social progress and personal progress, Beijing, South Korea and the United States will do their best to do their best. In the future, Beijing, South Korea and the United States will be committed to producing more high-quality and high-tech drugs and contribute to the country's medical industry.
Jiangxi Hairs Pharmaceutical Co., Ltd.
Dandong Kangfu Pharmaceutical Co., Ltd. is a subsidiary of Haiersi Pharmaceutical. The company is located on the banks of the beautiful Yalu River on the Liaodong Peninsula, facing North Korea across the river. The company has multiple preparation workshops to produce oral liquids and raw materials. Among them, the company produces "Lactulose oral solution" and has been awarded a national new product certificate issued by the National Science and Technology Commission. "Lactulose Oral Solution", "Compound Yimu Yangkeng Oral Liquid", and "Male Moth Ginseng and Antler Compound" won the gold medal at the China International New Technology and Technology Famous Products Expo, with brilliant achievements and many honors. "Ma Xing cough syrup" and "relieving heat and detoxification oral solution" have significant efficacy and are highly favored and praised by users.
Jiangxi Hairs Pharmaceutical Co., Ltd.
Dandong Kangfu Pharmaceutical Co., Ltd. is a subsidiary of Haiersi Pharmaceutical. The company is located on the banks of the beautiful Yalu River on the Liaodong Peninsula, facing North Korea across the river. The company has multiple preparation workshops to produce oral liquids and raw materials. Among them, the company produces "Lactulose oral solution" and has been awarded a national new product certificate issued by the National Science and Technology Commission. "Lactulose Oral Solution", "Compound Yimu Yangkeng Oral Liquid", and "Male Moth Ginseng and Antler Compound" won the gold medal at the China International New Technology and Technology Famous Products Expo, with brilliant achievements and many honors. "Ma Xing cough syrup" and "relieving heat and detoxification oral solution" have significant efficacy and are highly favored and praised by users.
Chongqing Jianneng Pharmaceutical Development Co., Ltd.
Chongqing Jianneng Pharmaceutical Development Co., Ltd. was established in 2003. It is a comprehensive pharmaceutical enterprise integrating drug research and development, drug marketing authorization, drug production and drug operation. It has established a complete drug research and development, production, sales and use of all life. Cycle quality management system. The company has 3 subsidiaries. Sichuan Jianneng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, is located in Zigong City, Sichuan Province and is the company's main pharmaceutical production base. Chongqing Xinjianneng Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary, is a specialized agency for drug research and development. The holding subsidiary Chongqing Dajianneng Pharmaceutical Co., Ltd. is the company's newly built pharmaceutical production base in Hechuan District. The company has many first-line clinical varieties in the fields of digestive system, respiratory system, etc. The company's sales network covers the whole country. Relying on a professional sales promotion team, the company, the Chinese Medical Association's Gastroenterology Branch, the Chinese Medical Association's Pediatrics Branch, the Chinese Medical Association's Allergics Branch and provincial branches. A close cooperative relationship has been established, through the scientific research results of experts, a company's product-related clinical application guide and expert consensus has been formed, and a rational clinical use of drugs is guided, and a professional brand of digestive endoscopic diagnosis and treatment drugs and children's medications are committed to creating a professional brand of gastroenterology diagnosis and treatment drugs and children's medications. In the future, the company will continue to increase R&D investment, expand the field of clinical application R&D, accelerate the layout of new products, and enhance the industry's competitive advantages. Always adhere to the mission of "I am healthy, I can", practice the business philosophy of "innovation and transcendence, work together, and share the future", and become one of the respected pharmaceutical companies, contributing to the realization of the health of the whole people.
Chongqing Jianneng Pharmaceutical Development Co., Ltd.
Chongqing Jianneng Pharmaceutical Development Co., Ltd. was established in 2003. It is a comprehensive pharmaceutical enterprise integrating drug research and development, drug marketing authorization, drug production and drug operation. It has established a complete drug research and development, production, sales and use of all life. Cycle quality management system. The company has 3 subsidiaries. Sichuan Jianneng Pharmaceutical Co., Ltd., a wholly-owned subsidiary, is located in Zigong City, Sichuan Province and is the company's main pharmaceutical production base. Chongqing Xinjianneng Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary, is a specialized agency for drug research and development. The holding subsidiary Chongqing Dajianneng Pharmaceutical Co., Ltd. is the company's newly built pharmaceutical production base in Hechuan District. The company has many first-line clinical varieties in the fields of digestive system, respiratory system, etc. The company's sales network covers the whole country. Relying on a professional sales promotion team, the company, the Chinese Medical Association's Gastroenterology Branch, the Chinese Medical Association's Pediatrics Branch, the Chinese Medical Association's Allergics Branch and provincial branches. A close cooperative relationship has been established, through the scientific research results of experts, a company's product-related clinical application guide and expert consensus has been formed, and a rational clinical use of drugs is guided, and a professional brand of digestive endoscopic diagnosis and treatment drugs and children's medications are committed to creating a professional brand of gastroenterology diagnosis and treatment drugs and children's medications. In the future, the company will continue to increase R&D investment, expand the field of clinical application R&D, accelerate the layout of new products, and enhance the industry's competitive advantages. Always adhere to the mission of "I am healthy, I can", practice the business philosophy of "innovation and transcendence, work together, and share the future", and become one of the respected pharmaceutical companies, contributing to the realization of the health of the whole people.
Beijing Chengji Pharmaceutical Co., Ltd.
Kaidashu is a lactulose oral solution product launched by Chengji Pharmaceutical. Beijing Chengji Pharmaceutical Co., Ltd. is located in the Zhongbei Industrial Zone (Beishicao Town) of Shunyi District. It was established in 2011. It is not only a national high-tech enterprise, but also a Zhongguancun high-tech enterprise. The company has an independent technology research and development center, attaches importance to the introduction of professional and technical talents, cooperates with many well-known universities and domestic R&D institutions, and is committed to the research and development of new drugs and generic drugs; and establishes the principle of equal importance of sales of new drugs and basic drugs, and strives to serve Public health. The company continues to pursue product quality improvement, put quality first, gradually improves the company's brand and influence, and develops and operates enterprises with the core and premise of providing solutions to mass health products. The company is deeply engaged in the field of pharmaceutical research and development and has established good cooperative relationships with many well-known domestic pharmaceutical research institutions and universities in the process of new drug research and development and transformation. According to the company's strategic plan, we focus on special preparation technologies suitable for children and innovation in high-end complex preparation technologies, creating special oral liquid preparations, micro-ball (ball) preparations, multi-layer tablet preparations, etc., in respiratory diseases, intestinal diseases, etc. We have created a domestic technological pioneer in the field, worked tirelessly to solve unmet clinical needs, and became a pioneer in innovation in medical characteristics. The company is committed to developing and producing innovative drugs and generic drugs that meet health needs, adhering to the original intention of "being honest and trustworthy, saving the world and saving people", and creating greater value for society.
Beijing Chengji Pharmaceutical Co., Ltd.
Kaidashu is a lactulose oral solution product launched by Chengji Pharmaceutical. Beijing Chengji Pharmaceutical Co., Ltd. is located in the Zhongbei Industrial Zone (Beishicao Town) of Shunyi District. It was established in 2011. It is not only a national high-tech enterprise, but also a Zhongguancun high-tech enterprise. The company has an independent technology research and development center, attaches importance to the introduction of professional and technical talents, cooperates with many well-known universities and domestic R&D institutions, and is committed to the research and development of new drugs and generic drugs; and establishes the principle of equal importance of sales of new drugs and basic drugs, and strives to serve Public health. The company continues to pursue product quality improvement, put quality first, gradually improves the company's brand and influence, and develops and operates enterprises with the core and premise of providing solutions to mass health products. The company is deeply engaged in the field of pharmaceutical research and development and has established good cooperative relationships with many well-known domestic pharmaceutical research institutions and universities in the process of new drug research and development and transformation. According to the company's strategic plan, we focus on special preparation technologies suitable for children and innovation in high-end complex preparation technologies, creating special oral liquid preparations, micro-ball (ball) preparations, multi-layer tablet preparations, etc., in respiratory diseases, intestinal diseases, etc. We have created a domestic technological pioneer in the field, worked tirelessly to solve unmet clinical needs, and became a pioneer in innovation in medical characteristics. The company is committed to developing and producing innovative drugs and generic drugs that meet health needs, adhering to the original intention of "being honest and trustworthy, saving the world and saving people", and creating greater value for society.
Abbott Trading (Shanghai) Co., Ltd.
Dumick is Abbott's oral lactulose solution product brand. In 1888, Dr. Wallace C. Abbott opened his own pharmacy and began to carefully prepare and produce drugs, aiming to provide patients and doctors with more effective treatment methods. Under the operation of Dr. Abbott, the company quickly became one of the founding companies in the pharmaceutical industry. Through continuous business expansion, leverage the company’s leadership in the new medical research field to meet growing global medical needs. While constantly entering new fields of the medical industry and expanding new markets, we have gradually established the company's tradition for a century - helping more people around the world live healthier and better. Over the past 130 years, Abbott has adapted to the increasingly complex medical environment and has always adhered to Abbott's original intention - to help the global public stay healthy at all stages of their lives. This is also the goal that Abbott continues to pursue in the future.
Abbott Trading (Shanghai) Co., Ltd.
Dumick is Abbott's oral lactulose solution product brand. In 1888, Dr. Wallace C. Abbott opened his own pharmacy and began to carefully prepare and produce drugs, aiming to provide patients and doctors with more effective treatment methods. Under the operation of Dr. Abbott, the company quickly became one of the founding companies in the pharmaceutical industry. Through continuous business expansion, leverage the company’s leadership in the new medical research field to meet growing global medical needs. While constantly entering new fields of the medical industry and expanding new markets, we have gradually established the company's tradition for a century - helping more people around the world live healthier and better. Over the past 130 years, Abbott has adapted to the increasingly complex medical environment and has always adhered to Abbott's original intention - to help the global public stay healthy at all stages of their lives. This is also the goal that Abbott continues to pursue in the future.
Fresenius Kabi (China) Investment Co., Ltd.
Ravir is affiliated to the German Fersenius Group and is a permeable laxative with lactulose as the main ingredient. Fresenius AG is a large multinational enterprise with a long history and significant influence on a global scale. The German Fersenius Group consists of four independent business units operating worldwide, namely: Fersenius Medical, Fersenius Kabi, Fersenius Hilius, and Fersenius Omede. Fresenius Cabi is a global enterprise focusing on the fields of infusion, blood transfusion and clinical nutrition. Fresenius Cabi's business scope is wide, covering various business areas such as medicines, clinical nutrition, and medical devices. Its main products include: 1. Clinical nutritional products: such as enteral nutritional preparations, used to meet the nutritional needs of patients with severe and chronic diseases. 2. Nephrology tumor products: such as drugs to delay renal failure, intravenous anesthetics, etc., used to treat renal diseases and tumor-related diseases. 3. Anesthesia surgery products: Provide a variety of anesthetic drugs and surgical-related medical devices to support the smooth progress of the surgical process. In addition, Fresenius Cabi is also committed to the research and development, production and sale of disposable consumables, active medical devices and accessories, and has a complete active precision infusion management system, as well as a product development and large-scale manufacturing industry chain. Taking care of life as his mission, Fresenius Cabi is committed to providing medical staff with essential medicines and technologies and helping them find quality solutions to their problems. Its corporate culture emphasizes customer first, quality first, integrity and integrity, win-win cooperation, persistence in innovation and enthusiastic commitment. Fresenius Cabi has a significant market position in the fields of infusion, blood transfusion and clinical nutrition. It has won wide recognition and praise for its outstanding products and technology, standardized management and the operation of R&D, production and marketing systems.
Fresenius Kabi (China) Investment Co., Ltd.
Ravir is affiliated to the German Fersenius Group and is a permeable laxative with lactulose as the main ingredient. Fresenius AG is a large multinational enterprise with a long history and significant influence on a global scale. The German Fersenius Group consists of four independent business units operating worldwide, namely: Fersenius Medical, Fersenius Kabi, Fersenius Hilius, and Fersenius Omede. Fresenius Cabi is a global enterprise focusing on the fields of infusion, blood transfusion and clinical nutrition. Fresenius Cabi's business scope is wide, covering various business areas such as medicines, clinical nutrition, and medical devices. Its main products include: 1. Clinical nutritional products: such as enteral nutritional preparations, used to meet the nutritional needs of patients with severe and chronic diseases. 2. Nephrology tumor products: such as drugs to delay renal failure, intravenous anesthetics, etc., used to treat renal diseases and tumor-related diseases. 3. Anesthesia surgery products: Provide a variety of anesthetic drugs and surgical-related medical devices to support the smooth progress of the surgical process. In addition, Fresenius Cabi is also committed to the research and development, production and sale of disposable consumables, active medical devices and accessories, and has a complete active precision infusion management system, as well as a product development and large-scale manufacturing industry chain. Taking care of life as his mission, Fresenius Cabi is committed to providing medical staff with essential medicines and technologies and helping them find quality solutions to their problems. Its corporate culture emphasizes customer first, quality first, integrity and integrity, win-win cooperation, persistence in innovation and enthusiastic commitment. Fresenius Cabi has a significant market position in the fields of infusion, blood transfusion and clinical nutrition. It has won wide recognition and praise for its outstanding products and technology, standardized management and the operation of R&D, production and marketing systems.
Yifan Pharmaceutical Co., Ltd.
Yifan Pharmaceutical (SZ: 002019) is an innovative R&D and production enterprise focusing on the field of medicine and health. It has built five major businesses in San Francisco, Shanghai, Beijing, Hangzhou and Hefei, focusing on the four core businesses of large molecules, small molecules, synthetic biology, and special Chinese medicine. Independent scientific research centers, fully coordinate with high-quality innovative resources at home and abroad, continue to increase innovation and research and development, and have initially formed a differentiated, diversified and competitive product research and development pipeline that meets clinical needs and has commercial value. Nearly 50 products under development cover Innovative drugs, biomimetic drugs, generic drugs, Chinese patent medicines, synthetic biology, etc. As a brand of lactulose oral solution under Yifan Pharmaceutical, La Wei has inherited Yifan Pharmaceutical's consistent innovative spirit and good quality.
Yifan Pharmaceutical Co., Ltd.
Yifan Pharmaceutical (SZ: 002019) is an innovative R&D and production enterprise focusing on the field of medicine and health. It has built five major businesses in San Francisco, Shanghai, Beijing, Hangzhou and Hefei, focusing on the four core businesses of large molecules, small molecules, synthetic biology, and special Chinese medicine. Independent scientific research centers, fully coordinate with high-quality innovative resources at home and abroad, continue to increase innovation and research and development, and have initially formed a differentiated, diversified and competitive product research and development pipeline that meets clinical needs and has commercial value. Nearly 50 products under development cover Innovative drugs, biomimetic drugs, generic drugs, Chinese patent medicines, synthetic biology, etc. As a brand of lactulose oral solution under Yifan Pharmaceutical, La Wei has inherited Yifan Pharmaceutical's consistent innovative spirit and good quality.
Beijing Maikang Pharmaceutical Co., Ltd.
Beijing Maikang Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in CBD Business Center, Chaoyang District, Beijing. Its production base is built in Miyun Economic Development Zone, Beijing, covering an area of 86 mu. It is a dedicated drug research and development, production and sales. An integrated modern enterprise. The company's R&D center was founded in 2011 and is committed to drug research and development. It has a standardized laboratory of more than 2,000 square meters. The research projects carried out include raw materials, oral solid preparations, oral liquid preparations, injections and other dosage forms, mainly involved in the therapeutic areas. There are digestive system, blood system, cardiovascular system, circulatory system, electrolytes, surgical medication, etc. Adhering to McConn's mission of "caring for health with science and technology and continuously providing professional medical products for the medical field", we will establish and continuously improve the quality management system for drug research and development, continuously provide high-quality pharmaceutical research services, and assist in pharmaceutical research and development and production. The company's production center was founded in 2012 and is committed to the production and manufacturing of pharmaceuticals. There is a 6400 square meters of oral solid and liquid production GMP workshop, with an annual production capacity of 40 million bags of oral solutions, 50 million bags of oral granules, and 50 billion tablets. The production of raw materials and injections is widely cooperated with the same industry, such as Sichuan Kelun Group. The company's sales center is mainly committed to the sales and promotion of products such as parenteral sodium sealing injection in the nursing field, lactulose oral solution in the digestive field, and prescription drugs. After nearly twenty years of hard work, we have a sound sales network and mature marketing channels. The marketing network currently covers all provinces and cities across the country and serves clinical patients. We have successfully established mature products and company brands in relevant clinical fields in the country.
Beijing Maikang Pharmaceutical Co., Ltd.
Beijing Maikang Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in CBD Business Center, Chaoyang District, Beijing. Its production base is built in Miyun Economic Development Zone, Beijing, covering an area of 86 mu. It is a dedicated drug research and development, production and sales. An integrated modern enterprise. The company's R&D center was founded in 2011 and is committed to drug research and development. It has a standardized laboratory of more than 2,000 square meters. The research projects carried out include raw materials, oral solid preparations, oral liquid preparations, injections and other dosage forms, mainly involved in the therapeutic areas. There are digestive system, blood system, cardiovascular system, circulatory system, electrolytes, surgical medication, etc. Adhering to McConn's mission of "caring for health with science and technology and continuously providing professional medical products for the medical field", we will establish and continuously improve the quality management system for drug research and development, continuously provide high-quality pharmaceutical research services, and assist in pharmaceutical research and development and production. The company's production center was founded in 2012 and is committed to the production and manufacturing of pharmaceuticals. There is a 6400 square meters of oral solid and liquid production GMP workshop, with an annual production capacity of 40 million bags of oral solutions, 50 million bags of oral granules, and 50 billion tablets. The production of raw materials and injections is widely cooperated with the same industry, such as Sichuan Kelun Group. The company's sales center is mainly committed to the sales and promotion of products such as parenteral sodium sealing injection in the nursing field, lactulose oral solution in the digestive field, and prescription drugs. After nearly twenty years of hard work, we have a sound sales network and mature marketing channels. The marketing network currently covers all provinces and cities across the country and serves clinical patients. We have successfully established mature products and company brands in relevant clinical fields in the country.
Lactulose Mylan is a generic lactulose solution used to treat constipation and hepatic encephalopathy, offering a cost-effective alternative.
Mylan Pharmaceuticals
Lactulose Mylan is a generic lactulose solution used to treat constipation and hepatic encephalopathy, offering a cost-effective alternative.
Lactulosa is a lactulose solution used for the treatment of constipation and hepatic encephalopathy, widely used in Spain and other countries.
Normon
Lactulosa is a lactulose solution used for the treatment of constipation and hepatic encephalopathy, widely used in Spain and other countries.
Lactulax is a lactulose solution used to treat constipation and to manage hepatic encephalopathy in patients with liver disease.
Intas Pharmaceuticals
Lactulax is a lactulose solution used to treat constipation and to manage hepatic encephalopathy in patients with liver disease.
Lactugal is a lactulose solution used to treat constipation and to reduce ammonia levels in patients with liver disease.
Galen Limited
Lactugal is a lactulose solution used to treat constipation and to reduce ammonia levels in patients with liver disease.
Heptalac is a lactulose solution marketed by Sandoz, used for the treatment of constipation and hepatic encephalopathy.
Sandoz
Heptalac is a lactulose solution marketed by Sandoz, used for the treatment of constipation and hepatic encephalopathy.
Cephulac is a lactulose solution used to treat constipation and to manage hepatic encephalopathy in patients with liver disease.
Hi-Tech Pharmacal
Cephulac is a lactulose solution used to treat constipation and to manage hepatic encephalopathy in patients with liver disease.
Enulose is a lactulose solution prescribed for the treatment of chronic constipation and hepatic encephalopathy.
Virtus Pharmaceuticals
Enulose is a lactulose solution prescribed for the treatment of chronic constipation and hepatic encephalopathy.
Generlac is a lactulose solution used to treat constipation and to reduce ammonia levels in patients with liver disease.
ANI Pharmaceuticals
Generlac is a lactulose solution used to treat constipation and to reduce ammonia levels in patients with liver disease.
Cumberland Pharmaceuticals
Kristalose is a crystalline form of lactulose, offering a convenient, pre-measured powder for the treatment of constipation and hepatic encephalopathy.
Cumberland Pharmaceuticals
Kristalose is a crystalline form of lactulose, offering a convenient, pre-measured powder for the treatment of constipation and hepatic encephalopathy.
Sun Pharmaceutical Industries
Lactulose Sun Pharma is a lactulose solution used to treat constipation and hepatic encephalopathy, offering a trusted treatment option globally.
Sun Pharmaceutical Industries
Lactulose Sun Pharma is a lactulose solution used to treat constipation and hepatic encephalopathy, offering a trusted treatment option globally.
